Opiant Pharmaceuticals
Pharmaceutical company; develops medicines for the treatment of addictions and overdose
Based in CA
🤖
AI Overview
With $940K in lobbying spend across 18 quarterly filings, Opiant Pharmaceuticals is an active lobbying client. Their lobbying covers 2 issue areas. Active from 2019 to 2023.
$940K
Total Spend
5
Years Active
1
Firms Hired
5
Lobbyists Deployed
2
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2019 | $0 |
| 2020 | $250K |
| 2021 | $330K |
| 2022 | $260K |
| 2023 | $100K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Pharmacy, Health Issues
- •Issues related to opioid addiction
- •Opioid epidemic, drug overdose, and national security threat posed by Fentanyl
- •Opioid epidemic, Fentanyl crisis,and Cannabinoid Overdose
- •Opioids/FDA
Related Analysis
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.